ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Group 1 - The Schall Law Firm is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. for potential violations of securities laws [1] - The investigation centers on whether Atara made false or misleading statements or failed to disclose important information to investors [2] - Atara received a Complete Response Letter (CRL) from the FDA regarding its EBVALLO Biologics License Application, which is related to a third-party manufacturing facility inspection [2] Group 2 - The CRL pertains to the treatment for adult and pediatric patients with Epstein-Barr virus positive post-transplant lymphoproliferative disease who have undergone at least one prior therapy [2]